Loading...
•
Dec 31, 2024
Inovio Q4 2024 Earnings Report
Inovio reported its fourth-quarter results with modest revenue and a narrowed net loss compared to the prior year, while advancing its clinical and regulatory milestones.
Key Takeaways
Inovio generated $117,000 in revenue in Q4 2024, a slight increase from the previous year. The company reported a net loss of $19.4 million for the quarter and continued its progress toward BLA submission and future clinical trials, while maintaining sufficient cash reserves.
Q4 revenue was $117,000, up from $103,000 year-over-year.
Net loss narrowed to $19.4 million compared to $25.0 million in Q4 2023.
Operating expenses decreased to $20.5 million from $27.5 million in the same period last year.
Cash, cash equivalents, and short-term investments totaled $94.1 million as of December 31, 2024.
Inovio
Inovio
Inovio Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Inovio expects to initiate its BLA rolling submission for INO-3107 in mid-2025 and continue advancing its clinical programs across various indications.
Positive Outlook
- BLA rolling submission for INO-3107 expected to start mid-2025.
- Promising interim results from DMAb technology trials showing sustained antibody production.
- Phase 3 trial preparation underway for INO-3112 in combination with LOQTORZI.
- Cash resources projected to support operations into Q1 2026.
- Continued strategic collaborations and potential for additional pipeline advancements.
Challenges Ahead
- Ongoing operational net losses projected.
- R&D expenses continue to pressure cash burn rates.
- Potential regulatory and trial delays may impact timelines.
- Competition in the DNA medicine and antibody space remains strong.
- Market conditions and future capital raising needs may present financial risks.